Title
Category
Credits
Event date
Cost
Treatment-Resistant Mood Disorders in LGBTQ People: A Retrospective Study of Clinical Features and Response to Electroconvulsive Therapy
  • Mood Disorders
  • Depression
  • Electroconvulsive Therapy
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this chart review, LGBTQ people with treatment-resistant mood disorders had clinical features linked to worse outcomes, but their improvement with ECT was similar to that seen in non-LGBTQ patients.
Remission and Treatment Augmentation of Depression in the United States
  • Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Closer monitoring of symptoms through measurement-based care and setting symptom remission as a goal can help improve outcomes for adults with depression.
The Efficacy of Measurement-Based Care for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials
  • Depression
  • Delivery of Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
For patients with depressive disorders treated with pharmacotherapy, measurement-based care is effective in decreasing symptom severity, promoting remission, and improving medication adherence.
Postpartum Depression and Psychosis and Subsequent Severe Mental Illnesses in Mothers and Neurodevelopmental Disorders in Children: A Nationwide Study
  • Bipolar Disorder
  • Depression
  • Attention-Deficit/Hyperactivity Disorder
  • Autism Spectrum Disorders
  • Child and Adolescent Psychiatry
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Women’s Mental Health
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Is there an association between postpartum depression or psychosis and subsequent disorders in either the mother or the child who is exposed to postpartum maternal illness?
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.